Respiratory disease in cystic fibrosis: From pathophysiology to therapy;Atteinte respiratoire au cours de la mucoviscidose: De la physiopathologie a la therapeutique

Revue des Maladies Respiratoires

Volumn 16, Issue 4, 1999, Pages 495-509

  Reynaud Gaubert, M ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

CFTR; Cystic fibrosis; Physiopathology; Therapeutics

Indexed keywords

ARTICLE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; GENE EXPRESSION; GENE MUTATION; GENE TRANSFER; LUNG INFECTION; PATHOPHYSIOLOGY; PNEUMONIA; RESPIRATORY TRACT DISEASE; SURVIVAL;

ADULT; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FORECASTING; GENE THERAPY; HUMANS; INFLAMMATION; RESPIRATORY TRACT DISEASES;

EID: 0032879557     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (143)

1. ELBORN JS, SHALE DJ, BRITTON JR : Cystic fibrosis: Current survival and population estimates to the year 2000. Thorax 1991;46:881-5
2. KEREM B, ROMMENS JM, BUCHANAN JA et al. : Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-80.
3. RIORDAN JR, ROMMENS JM, KEREM B et al. : Identification of the cystic fibrosis gene : cloning and characterization of complementary DNA. Science 1989;245:1066-73.
4. ZIELENSKI J, ROZMAHEL R, BOZON D et al. : Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 1991;10:214-28.
5. STEWART B, ZABNER J, SHUBER AP, WELSH MJ, MCCRAY PB : Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. Am J Respir Crit Care Med 1995;151:899-903.
6. DELMARCO A, PRADAL U, CABRINI G, BONIZZATO A, MASTELLA G : Nasal potential difference in cystic fibrosis patients presenting borderline sweat test. Eur Respir J 1997;10:1145-9
7. DUPERREX O, BERCLAZ PY, BERTRAND D, LACROIX JS, POCHON N, BELLI D, ROCHAT : A new device for in vivo measurement of nasal transepithelial potential difference in cystic fibrosis patients and normal subjects. Eur Respir J 1997;10:1631-6.
8. HOFMANN T, BOHMER O, HULS G et al : Conventional and modified nasal potential-difference measurement in cystic fibrosis. Am J Respir Crit Care Med 1997;155:1908-13.
9. CAZENEUVE C, GIRODON E, COSTES B, GOOSSENS M : La mucoviscidose: le gène et sa protéine. In : C. Caulin, C. Chastang, eds. Recherche Clinique et Décision Thérapeutique, Les médicaments de la mucoviscidose chez l'enfant. Springer-Verlag France, Paris, 1997:1-14.
10. PUCHELLE E, GAILLARD D, PLOTON D et al. : Differential localization of the cystic fibrosis transmembrane conductance regulator in normal and cystic fibrosis airway epithelium. Am J Respir Cell Mol Biol 1992;7:485-91.
11. JACQUOT J, PUCHELLE E, HINNRASKY J : Localization of the cystic fibrosis transmembrane conductance regulator in airway secretory glands. Eur Respir J 1993;6:169-76.
12. ENGELHARDT JF, ZEPEDA M, COHN J, YANKASKAS JR, WILSON JM : Expression of the cystic fibrosis gene in adult human lung. J Clin Invest 1994;93:737-49.
13. QUINTON PM : Cystic fibrosis: a disease in electrolyte transport. FASEB J 1990;4:2709-17.
14. WELSH MJ, SMITH AE : Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993;73:1251-4.
15. FRIZZELL RA : Functions of the cystic fibrosis transmembrane conductance regulator protein. Am J Respir Crit Care Med 1995;151:S54-S8.
16. - channels by protein kinase A corrected by insertion of CFTR. Science 1992;358:581-4.
17. SCHWIEBERT EM, EGAN ME, HWANG TH et al. : CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP. Cell 1995;81:1063-73.
18. STUTTS MJ, CANESSA CM, OLSEN JC et al. : CFTR as a c-AMP-dependent regulator of sodium channels. Science 1995;269:847-50.
19. BRADBURY NA, JILLING T, BERTA G, SORSCHER EJ, BRIDGES RJ, KIRK KL : Regulation of plasma membrane recycling by CFTR. Science 1992;256:530-2.
20. BOUCHER RC : Human airway in ion transport (pt 1). Am J Respir Crit Care Med 1994;150:271-81.
21. BOUCHER RC : Human airway in ion transport (pt 2). Am J Respir Crit Care Med 1994;150:581-93.
22. TÜMMLER B, PUCHELLE E : CFTR: a multi-faced epithelial molecule. Trends in Cell Biol 1997;7:250-1.
23. IMUNDO L, BARASCH J, PRINCE A, AL-AWQATI Q : Cystic fibrosis epithelial cells have receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci USA 1995;92:3019-23.
24. PILEWSKI JM, LATOCHE JD, ARCASOY SM, ALBELDA SM : Expression of integrin cell adhesion receptors during human airway epithelial repair in vivo. Am J Physiol 1997;273:L256-63.
25. PIER G, GROUD M, ZAIDI TS et al. : Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996;27: 64-7.
26. SMITH JJ, TRAVIS SM, GREEBERG EP, WELSH MJ : Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996;85:229-32.
27. GOLDMAN MJ, ANDERSON GM, STOLZENBERG ED, KARI UP, ZASLOFF M, WILSON JM : Human β-defensine-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997;88:553-60
28. HO LP, SAMWAYS JM, PORTEOUS DJ et al. : Correlation between nasal potential difference measurements, genotype and clinical condition in patients with cystic fibrosis. Eur Respir J 1997;10:2018-22
29. KEREM E, COREY M, KEREM SB et al. : The relation between genotype and phenotype in cystic fibrosis- Analysis of the most common mutation (ΔF508). N Engl J Med 1990;323:1517-22.
30. HUBERT D, BIENVENU T, DESMAZES-DUFEU N et al. : Genotype-phenotype relationships in a cohort of adult cystic fibrosis patients. Eur Respir J 1996;9:2207-14.
31. TSUI LC, DURIE P : Genotype and phenotype in cystic fibrosis. Hosp Pract Off Ed 1997;32:115-8, 123-9, 134.
32. PIGNATTI PF, BOMBIERI C, MARIGO C, BENETAZZO M, LUISETTI M : Increasd incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. Hum Mol Genet 1995;4:635-9.
33. GIRODON E, CAZENEUVE C, LEBARGY F et al. : CFTR gene mutations in adults with disseminated bronchiectasis. Eur J Hum Genet 1997;5:149-55.
34. KAHN TZ, WAGENER JJ, BOST T : Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-82.
35. BALOUGH K, MCCUBBIN M, WEINBERER M : The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995;20:63-70.
36. CANTIN A : Cystic fibrosis lung inflammation: early, sustained and severe. Am J Respir Crit Care Med 1995;151:939-41.
37. DERELLE J : Inflammation. Référence Mucoviscidose 1997,2:26-9.
38. ARMSTRONG DS, GRIMWOOD K, CARLIN JB et al. : Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997;156:1197-1204.
39. SHUTE JK : IL8 in cystic fibrosis and its regulation by complexation with macromolecules. 10th Annual North American Cystic Fibrosis Conference, Orlando, Florida, USA, 24-27 October 1996. Pediatr Pulmonol 1996;(supp13):187-188.
40. NOAH TL, BLACK HR, CHENG PW, WOOD RE, LEIGH MW : Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 1997;175:638-47
41. BONFIELD TL, PANUSKA JR, KONSTAN MW et al. : Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995;152:2111-8.
42. JANOFF A, WHITE R, CARP H, HAREL S, DEARING R, LEE D : Lung injury induced by leukocytic proteases. Am J Pathol 1979;97:111-36;
43. MOSS RB, BOCIAN RC, HSU YP, WEI T, YSSEL H : Reduced interleukin-10 production by cystic fibrosis T cell clones. Am J Respir Crit Care Med 1995;151:A248
44. PUCHELLE E, JACQUOT J : Fonctions de la protéine CFTR dans l'épithélium respiratoire et ses anomalies dans la mucoviscidose. In : C. Caulin, C. Chastang, eds. Recherche Clinique et Décision Thérapeutique. Les médicaments de la mucoviscidose chez l'enfant. Springer-Verlag France, Paris, 1997:33-44.
45. GRASEMAN H, MICHLER E, IOANNIDIS I, DE GROOT H, RATJEN F : Airway nitric oxide (NO) in CF lung disease. Pediatr Pulmonol 1996;(supp13):331.
46. FOUCAUD P : Infection broncho-pulmonaire. Référence Mucoviscidose 1997,2:22-5.
47. MARELICH GP, CROSS CE : Cystic fibrosis in adults. From researcher to practitionner. West J Med 1996;164:321-34.
48. RAMSEY BW : Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335:179-88.
49. STAFANGER G, GARNE P, HOWITZ P, MORKASSEL E, KOCH C : The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J 1988;161-7.
50. APP EM, BARAN D, DAB I et al. : Efficacy, safety and tolerability of chronic inhalation therapy with Nacystelyn versus placebo in cystic fibrosis patients. Am J Respir Crit Care Med 1997;155(4):A199.
51. DASGUPTA B, KING M : Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with Nacystelyn and rhDNase. Pediatr Pulmonol 1996;22:161-6.
52. LAUBE BL, AUCI RA, SHIELDS DE et al. : Effects of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Am J Respir Crit Care Med 1996;153:752-60.
53. RAMSEY BW, ASTLEY SJ, AITKEN ML et al. : Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993;148:145-51.
54. SHAH PL, SCOTT SF, GEDDES DM, HODSON ME : Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med 1995;89:499-502.
55. HODSON ME : Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis. Am J Respir Crit Care Med 1995;151:S70-S74.
56. FUCHS HJ, BOROWITZ DS, CHRISTIANSEN DH et al. : Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-42.
57. MCCOY K, HAMILTON S, JOHNSON C FOR THE PULMOZYME STUDY GROUP : Effects of 12 week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 1996;110:889-95.
58. DAVIES J, TRINDADE MT, WALLIS C, ROSENTHAL M, CRAWFORD O, BUSH A : Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol 1997;23:243-8.
59. EISENBERG JD, AITKEN ML, DORKIN HL et al. : Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J Pediatr 1997;131:118-24.
60. CONWAY SP : Recombinant human DNase (rhDNase) in cystic fibrosis: is it cost effective? Arch Dis Child 1997;77:1-3.
61. ROBINSON M, REGNIS JA, BAILEY DL, KING M, BAUTOVICH GJ, BYE PT : Effect of hypertonic saline, amiloride and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996;153:1503-9.
62. ENG PA, MORTON J, DOUGLASS JA, RIEDLER J, WILSON J, ROBERTSON M : Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996;21:77-83.
63. KING M, DASGUPTA B, TOMKIEWICZ RP, BROWN NE : Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 1997;156:173-7.
64. KONIG PD, GAYER D, BARBERO GJ, SHAFFER J : Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. Pediatr Pulmonol 1995;20:205-14.
65. BARGON J, VIEL K, DAULETBAEV N, WIEWRODT R, BUHL R : Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients. Eur Respir J 1997;10:2307-11.
66. SANCHEZ I, DE KOSTER J, HOLBROW J, CHERNICK V : The effect of high doses of inhaled salbutamol and ipratropium bromide in patients with cystic fibrosis. Chest 1993;104:842-6.
67. SANCHEZ I : Role of anticholinergic agents in the treatment of cystic fibrosis. Arch Pediatr 1995;2:154S-158S.
68. 2 adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis. Chest 1993;103:805-11.
69. ISLES A, SPINO M, TABACHNIK E, LEVISON H, THIESSEN J, MCLEOD S : Theophilline disposition in cystic fibrosis. Am Rev Respir Dis 1983;127:417-21.
70. AUERBACH HS, WILLIAMS M, KIRKPATRICK JA, COLTEN HR : Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985;2:686-8.
71. EIGEN HR, ROSENSTEIN BJ, FITZSIMMONS S, SHIDLOW DV : A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995;126:515-23.
72. ROSENSTEIN BJ, EIGEN H : Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics 1991;87:245-6.
73. NIKOLAIZIK WH, SCHÖNI MH : Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr 1996;128:271-4.
74. NIEMAN R, WILLIAMS S, MADEN C, KNIGHT R, HODSON M : A double-blind, placebo-controlled study comparing the inhaled corticosteroid fluticasone propionate with placebo in adults with cystic fibrosis. Am J Respir Crit Care Med 1996;153:A72.
75. BISGAARD H, PEDERSEN SS, NIELSEN KG et al. : Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary pseudomonas aeruginosa infection. Am J Respir Crit Care Med 1997;156:1190-6.
76. KONSTAN MW, BYARD PJ, HOPPEL CL, DAVID PB : Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-54.
77. KONSTAN MW, FITZSIMMONS SC : Clinical use of Ibuprofen for cystic fibrosis (CF) lung disease: data from the 1996 CF Foundation National Patient Registry. Pediatr Pulmonol 1991;suppl 14:A427
78. WINNIE GB, COWAN RG, WADE NA : Intraveinous immune globuline treatement of pulmonary exacerbations in cystic fibrosis. J Pediatr 1989;114:309-14.
79. VANWYE JE, COLLINS MS, BAYLOR M et al. : Pseudomonas hyperimmune globuline passive immunotherapy for pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 1990;9:7-18.
80. BEARDSMORE CS, THOMPSON JR, WILLIAMS A et al. : Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment. Arch Dis Child 1994;71:133-7.
81. MICHEL BC : Antibacterial therapy in cystic fibrosis. A review of the literature published between 1980 and February 1987. Chest 1988;94:129S-140S.
82. ARRIETA A : Use of meropenem in the treatment of serious infections in children: review of the current literature. Clin Infect Dis 1997;24(suppl 2):S207-12.
83. LE BOURGEOIS M, GERARDIN M, MUNCK A, NAVARRO J : Mucoviscidose. Prise en charge antibiotique. Presse Med 1997;26:727-32.
84. REY E, TRÉLUYER JM, PONS G : Les modifications pharmacocinétiques au cours de la mucoviscidose. In : C. Caulin, C Chastang, eds. Recherche Clinique et Décision Thérapeutique. Les médicaments de la mucoviscidose chez l'enfant. Springer-Verlag France, Paris 1997:119-42.
85. CHURCH DA, KANGA JF, KUHN RJ, RUBIO TT, SPOHN WA et al. : Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/ tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. Pediatr Infect Dis J 1997;16:97-105;123-6.
86. PHILLIPS AM : Home intravenous antibiotic therapy: practical aspects in adults. JR Soc Med 1991;90(suppl.31):34-6.
87. FREDERIKSEN B, KOCK C, HOIBY N : Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-5.
88. STUTMAN HR : An american approach to the management of P. aeruginosa infection in cystic fibrosis. Pediatr Pulmonol 1996;suppl 13:109-10.
89. JENSEN T PEDERSEN SS, HOIBY N, KOCH C, FLENSBORG EW : Use of antibiotics in cystic fibrosis: the Danish approach. Antibiot Chemother 1989;42:237-46.
90. FREDERIKSEN B, LANG S, KOCK C, HOIBY N : Improved survival in the Danish center-treated cystic fibrosis patients: results of agressive treatment. Pediatr Pulmonol 1996;21:153-8.
91. SHELDON CD, ASSOUFI BK, HODSON ME : Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. Respir Med 1993;87:587-93.
92. DODD ME, ABBOTT J, MADDISON J, MOORCROFT AJ, WEBB AK : Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 1997;52:656-8.
93. TOSO C, WILLIAMS DM, NOONE PG : Inhaled antibiotics in cystic fibrosis: a review. Ann Pharmacother 1996;30(7-8):840-50.
94. HOEKSTRA MO, VAN-AALDEREN WM : Nebulised antipseudomonal antibiotic therapy in cystic fibrosis. Thorax 1997;52:398-9.
95. DIOT P, GAGNADOUX F, MARTIN C et al. : Nebulization and anti-Pseudomonas aeruginosa activity of colistin. Eur Respir J 1997;10:1995-8.
96. WEBER A, MORLIN G, COHEN M, WILLIAM-WARREN J, RAMSEY B, SMITH A : Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol 1997;23:249-60.
97. MUKHOPADHYAY S, SINGH M, CATER JI, OGSTON S, FRANKLIN M, OLVER RE : Nebulised anti-pseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax 1996;51:364-8.
98. TOUW DJ, BRIMICOMBE RW, HODSON ME, HEIJERMAN HGM, BAKKER W : Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995;8:1594-1604.
99. TOUW DJ, JACOBS FA, BRIMICOMBE RW, HEIJERMAN HG, BAKKER W, BRIEMER DD : Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1997;41(1):184-7
100. RAMSEY BW, DORKIN HL, EISENBERG JD, GIBSON RL et al. : Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Eng J Med 1993;328:1740-6.
101. VASCONCELLOS CA, ALLEN PG, WOHL ME, DRAZEN JM, JANMEY PA, STÖSSEL TP : Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994;263:969-71.
102. MC ELVANEY NG, HUBBARD RC, BIRRER P et al. : Aerosol alpha-1-antitrypsin treatment of cystic fibrosis. Lancet 1991;337:392-4.
103. ALLEN ED : Opportunities for the use of aerosolized alpha-1-antitrypsin for the treatment of cystic fibrosis. Chest 1996;110(suppl 6):256s-60s.
104. ARONOFF SC, QUINN FJ, CARPENTER LS, NOVICK WJ : Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis: preliminary observations. J Pediatr 1994;125:992-7.
105. SMITH JJ, MCCRAY PB, THORNE S, LOURY DJ, FIDDES JC, WELSH MJ : Synthetic protegrins can eliminate P. aeruginosa from the mucosal surface of cultured airway epithelia. Pediatr Pulmonol 1997;Suppl 14:A428.
106. RAMSEY B, BURNS J, SMITH A : Safety and efficacy of Tobramycin solution for inhalation in patients with cystic fibrosis: The results of two Phase III placebo controlled clinical trial. Pediatr Pulmonol 1997;Suppl 14:137-8.
107. DRUMM ML, POPE HA, CLIFF WH et al. : Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfert. Cell 1990;62:1227-33.
108. CURIEL D, PILEWSKI J, ALBELDA S : Gene therapy approaches for inherited lung diseases. Am J Resp Cell Mol Biol 1996;14:1-18.
109. KNOWLES M, HOHNEKER K, ZHOU Z, OLSEN J, NOAH T, HU P et al. : A controlled study of adenoviral-vector-mediated gene transfert in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1993;333:823-31.
110. CRYSTAL RG, MCELVANEY NG, ROSENFELD MA, CHU C et al. : Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genet 1994;8:42-51.
111. BELLON G, CALEMARD L, THOUVENOT D et al. : Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Therapy 1997;8:15-25.
112. BELLON G: Thérapie génique. Référence Mucoviscidose 1997;2:58-60.
113. BELLON G, LEVREY H, FAU C, PAVIRANI A : La thérapie génique des manifestations respiratoires de la mucoviscidose. In : C. Caulin, C. Chastang, eds. Recherche Clinique et Décision Thérapeutique. Les médicaments de la mucoviscidose chez l'enfant. Springer-Verlag France, Paris, 1997:165-79.
114. MEHTALI M, PAVIRANI A : À la quête du vecter idéal. Référence Mucoviscidose 1997;2:50-2.
115. ELEVENTH ANNUAL NORTH AMERICAN CYSTIC FIBROSIS CONFERENCE : Nashville, Tennessee, October 23-26, 1997. Pediatr Pulmonol 1997;suppl 14:255-61 (Abstracts).
116. TENTH ANNUAL NORTH AMERICAN CYSTIC FIBROSIS CONFERENCE : Orlando, Florida, October 24-26, 1996. Pediatr Pulmonol 1996;suppl 13:91-96 (Abstracts).
117. ZABNER J, RAMSEY BW, MEEKER DP et al. : Repeat administration of an adenovirus vector encoding CFTR to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 1996;97:1504-11.
118. HARVEY BG, SIKAND V, BRION P, KANER RJ, CRYSTAL RG : Repeat administration of AdCFTR to the airway epithelium of individuals with cystic fibrosis is well tolerated and associated with minimal systemic humoral immunity. Pediatr Pulmonol 1997;suppl 14:A182;
119. FLOTTE T, CARTER B, CONRAD C et al. : A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 1996;7:1145-59.
120. GILL DR, SOUTHERN KW, MOFFORD KA et al. : A placebo-controlled study of liposome-mediated gene transfert to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997;4:199-209.
121. PORTEOUS DJ, DORIN JR, MCLACHLAN G, DAVIDSON-SMITH H, DAVIDSON H et al. : Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997;4:210-8
122. KOLLEN W, ERBACHER P, MIDOUX P et al. : Glycosylated polylysines. Nonviral vectors for gene transfert into cystic fibrosis airway epithelial cells. Chest 1991;111(suppl. 6): 95S-6S.
123. PUCHELLE E, JACQUOT J, DUPUIT F, GAILLARD D : Quelles cellules respiratoires cibler? Référence Mucoviscidose 1997;2:53-7.
124. KNOWLES MR, CHURCH NL, WALTNER WE et al. : A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990;322:1189-94.
125. GRAHAM A, HASANI A, ALTON EW et al. : No added benefit from nebulised amiloride in patients with cystic fibrosis. Eur Respir J 1993;6:1243-8.
126. BOWLER IM, KELMAN B, WORTHINGTON D et al. : Nebulized amiloride in respiratory exacerbations of cystic fibrosis : a randomized controlled trial. Arch Dis Child 1995;73:427-30.
127. PONS G, MARCHAND MC, FOUCARD C et al. : French multicenter randomized double-blind placebo controlled trial of nebulized amiloride in cystic fibrosis patients. Pediatr Pulmonol 1995;suppl. 12:193 (Abstract).
128. HOFMANN T, SENIER I, BITTNER P, HULS G, SCHWANDT HJ, LINDEMANN H : Aerosolized amiloride: Dose-effect on nasal bioelectric properties, pharmacokinetics, and effects on sputum expectoration in patients with cystic fibrosis. J Aerosol Med 1997;10:147-58.
129. HOFMANN T, ZIERSCH A, SENIER I et al. : Benzamil and amiloride in CF nasal epithelium: Time course of the effects on nasal potential difference in vivo. Pediatr Pulmonol 1996;suppl 13:280 (Abstract).
130. BLANK U, CLAUSS W, WEBER WM : Effects of benzamil in human cystic fibrosis airway epithelium. Cell Physiol Biochem 1995;5:385-90.
131. KNOWLES MR, CLARKE LL, BOUCHER RC: Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 1991;325:533-8.
132. REGNIS JA, LAZAROWSKI ER, FOY CE, BOUCHER RC, KNOWLES MR : Uridine 5′-triphosphate metabolism by human epithelial cells, whole blood and plasma in vitro. Am J Respir Crit Care Med 1996;153:A779.
133. OLIVIER KN, BENNETT WD, HOHNEKER KW et al. : Acute safety and effects on mucociliary clearance of aerosolized uridine 5′-triphosphate +/- amiloride in normal human adults. Am J Respir Crit Care Med 1996;154:217-23.
134. BENNETT WD, OLIVIER KN, ZEMAN KL, HOHNEKER KW, BOUCHER RC, KNOWLES MR : Effect of uridine 5′-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Respir Crit Care Med 1996;153:1796-801.
135. HOWARD M, FRIZELL RA, BEDWELL DM : Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996;2:467-9.
136. BEDWELL D, KAENJAK A, BEBOK Z et al. : Gentamicin restores endogenous CFTR expression and function by suppressing premature stop mutations. Pediatr Pulmonol 1997;supp 14:A 233.
137. ZEITLIN PL, RUBENSTEIN RC : Phenylbutyrate therapy for cystic fibrosis. Pediatr Pulmonol 1997;(supp 14):S84:132.
138. RUBENSTEIN RC AND ZEITLIN PL : A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in ΔF508-homozygous cystic fibrosis patients. Partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998;157:484-90.
139. COHEN BE, LEE G, JACOBSON KA et al. : CPX (8-cyclopentyl-1, 3-dipropylxanthine) and other alkyl-xanthines differentially bind to the wild-type and ΔF508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. Biochemistry 1997;36:6455-61.
140. CASAVOLA V, TURNER RJ, GUAY-BRODER C, JACOBSON KA, EIDELMAN O, POLLARD HB : CPX, a selective Al-adenosine-receptor antagonist, regulates intracellular pH in cystic fibrosis cells. Am J Physiol 1995;269:C226-C33.
141. KELLY TJ, THOMAS KR, MILGRAM LJH, DRUMM ML : In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant ΔF508 in murine nasal epithelium. Proc Natl Acad Sci USA 1997;94:2604-8.
142. YANG IC, CHENG TH, WANG F, PRICE EM, HWANG TC : Modulation of CFTR chloride channels by calyculin and genistein. Am J Physiol 1997;272:C141-C55.
143. LALLEMAND JY, STOVEN V, ANNEREAU JP et al. : Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis? Lancet 1997;350(9079):711-2.